top of page
Browse by category
Search
Ascletis reveals pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection
Ascletis Pharma has announced pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies in...
Ascletis reveals positive interim results from first two cohorts of MAD study of small molecule oral GLP-1R agonist ASC30
Ascletis Pharma has revealed positive interim results from the first two cohorts of its randomised, double-blind, placebo-controlled...
Positive results for Ascletis’ oral GLP-1ra ASC30
Ascletis Pharma has announced positive topline results from its US single ascending dose (SAD) study of ASC30 oral tablet in patients...
Muscle-preserving weight loss drug ASC47 plus semaglutide is superior to semaglutide monotherapy for weight loss
Ascletis Pharma has revealed in a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg,...
Ascletis' announces promising results for ASC47 adipose-targeted THRβ
Ascletis Pharma has announced that results of its Phase I single ascending dose (SAD) study in Australia in subjects with elevated...
Browse by tag
bottom of page